The Beta-Blocker Heart Attack Trial was a placebo• controlled, randomized, double-blind clinical trial of the long-term administration of propranolol hydrochloride to patients who had had at least one myocardial infarc• tion. Among 3,837 patients followed up for an average of 25 months, 3,290 (85.7%) had 24 hour ambulatory electrocardiograms performed at the baseline exami• nation. Four classifications of arrhythmia were exam• ined. One of these, the presence of complex ventricular arrhythmias (at least 10 ventricular premature beats/h, or at least one pair or run of ventricular premature beats or multiform ventricular premature beats) was the subgroup of major interest. Regardless of the classifi• cation, the presence of arrhythmia identifies a group of patients with a higher risk of total mortality, coronary heart disease mortality, sudden cardiac death and in• stantaneous cardiac death.
The Beta-Blocker Heart Attack Trial was a placebo• controlled, randomized, double-blind clinical trial of the long-term administration of propranolol hydrochloride to patients who had had at least one myocardial infarc• tion. Among 3,837 patients followed up for an average of 25 months, 3,290 (85.7%) had 24 hour ambulatory electrocardiograms performed at the baseline exami• nation. Four classifications of arrhythmia were exam• ined. One of these, the presence of complex ventricular arrhythmias (at least 10 ventricular premature beats/h, or at least one pair or run of ventricular premature beats or multiform ventricular premature beats) was the subgroup of major interest. Regardless of the classifi• cation, the presence of arrhythmia identifies a group of patients with a higher risk of total mortality, coronary heart disease mortality, sudden cardiac death and in• stantaneous cardiac death.
Propranolol and other beta-receptor blocking agents have been shown in clinical trials to decrease mortality (1-3) and reduce ventricular premature beat frequency (4) (5) (6) in pa• tients who have had myocardial infarction. Prospective ep• idemiologic studies (7) (8) (9) (10) (11) found relations between the pres• ence of ventricular premature beats and increased mortality in such patients. One might, therefore, expect propranolol to be especially effective in patients with myocardial in• farction and ventricular premature beats.
The Beta-Blocker Heart Attack Trial was a placebo-con• trolled, randomized, double-blind clinical trial of the long• term administration of propranolol in patients who had had at least one documented myocardial infarction. A total of 3,837 patients in 31 centers were assigned to two groups (1,916 patients to propranolol, 180 or 240 mg/day, and 1,921 patients to matching placebo) and followed up for an
The a priori subgroup hypothesis that sudden death would be preferentially reduced by prppranolol in pa• tients with complex ventricular arrhythmias was not supported. The relative benefit of propranolol in reduc• ing sudden death for this subgroup was 28 versus 16% for the subgroup without ventricular arrhythmia (rel• ative risk of 0.72 versus 0.84, a nonsignificant relative difference of 14%). There were similar findings for two of the three other classifications of arrhythmia and for the other response variables. Although propranolol does not appear to be of special relative benefit in patients with ventricular arrhythmia, the presence of the ar• rhythmia does identify a high-risk group. The mecha• nism by which propranolol reduces mortality is still un• clear, but is probably not solely an antiarrhythmic one.
(J Am Coil CardioI1986;7:1-8) average of 25 months. A previous publication by the Beta• Blocker Heart Attack Trial (1) reported a 26% reduction of total mortality in patients with previous myocardial infarc• tion assigned to propranolol therapy as compared with sim• ilar patients assigned to a placebo. Cause-specific mortality analyses indicated that both sudden and nonsudden coronary heart disease mortality were decreased in the propranolol group. A second paper by the Beta-Blocker Heart Attack Trial research group (12) reported on coronary event inci• dence (coronary heart disease mortality plus nonfatal myo• cardial infarction) and nonfatal events. Coronary event in• cidence was 23% lower in the propranolol-treated group and nonfatal reinfarction was 16% lower. This report considers the effect of propranolol therapy on coronary deaths in patients with ventricular arrhythmias at the time of enrollment, as determined by means of 24 hour ambulatory electrocardiograms. One of the protocol• specified subgroup hypotheses of the Beta-Blocker Heart Attack Trial was that propranolol would be particularly ef• fective in reducing sudden cardiac death (that is, death within 1 hour of onset of symptoms) in patients with complex ventricular premature beats. Other end points (total mor• tality, coronary heart disease mortality and instantaneous cardiac death) and adverse effects, as well as other classi• fications of ventricular arrhythmia, are also examined.
Methods
Study design. Recruitment for study participants began on June 19, 1978 and ended on October 2, 1980. Men and women aged 30 to 69 years who were hospitalized with symptoms and electrocardiographic and enzymatic changes compatible with an acute myocardial infarction were can• didates for enrollment in the trial. Reasons for exclusion from the study included medical contraindications to pro• pranolol, life-threatening illness other than coronary heart disease and the use of beta-receptor blocking drugs by the patient. Informed consent was obtained from all patients in the study. They were enrolled 5 to 21 days after hospital admission, while they were still hospitalized. Follow-up visits were scheduled at 1 month, 6 weeks and 3 months after randomization, and at subsequent 3 month intervals. A detailed description of the Beta-Blocker Heart Attack Trial design and methods has been reported elsewhere (13) .
Holter monitoring. Ambulatory electrocardiographic monitoring was encouraged at baseline, but was not man• datory for patient enrollment. At the 6 week visit, a second 24 hour ambulatory electrocardiogram was performed on 840 randomly selected patients representing approximately 25% of the number performed at bas!:!line.
The 24 hour, two channel, reel to reel Holter magnetic tapes were generated on Avionics model No. 445 recorders and processed by the CardioData system which is digital, software-based (the Worcester Polytechnic Institute algo• rithm) (14) and capable of differentiating up to 25 different electrocardiographic variables involving rate and rhythm change. As electrocardiogram complexes are noted by the computer, an operator verifies the decision, thus providing human interaction with the computer. The CardioData sys• tem analysis method has been validated (14) both for ac• curacy and precision for ventricular premature beat detec• tion. A quality control program involved the blinded analysis of several nand-counted tapes and reanalysis of selected Beta-Blocker Heart Attack Trial tapes.
Arrhythmia definitions. The patient subgroup of major interest, as specified in the protocol, had complex ventric• ular premature beats defined as the presence of one or more of the following features on the 24 hour electrocardiogram recordings: multiform ventricular premature beats, an av• erage of at least 10 ventricular premature beats/h on the 24 hour recording or at least one pair or run of ventricular premature beats. Multiform ventricular premature beats were defined as beats with varying configuration, in either chan• nel, noted visually by the scanning technician and confirmed by the supervising cardiologist.
Because ventricular ectopic activity is categorized by differing criteria in other reports, three other patient subgroups are also cqnsidered in this report. These are: 1) patients with JACC Vol 7, No 1 January 1986.1-8 at least one ventricular premature beat during the monitoring period; 2) patients with an average of at least 10 ventricular premature beats/h; and 3) patients with an average of at least 10 ventricular premature beats/h plus at least one pair or run of ventricular premature beats plus multiform ventricular premature beats.
Statistics. In making comparisons between the two groups, the risk of having a cardiac event in the propranolol• treated group relative to the placebo-treated group (relative risk) was calculated. A relative risk of less than 1 indicates a lower observed incidence of the specified events in the propranolol-treated group. When many subgroup compar• isons are made, interpretation of statistical significance is difficult because there is an increased probability of ob• serving p values below an arbitrary significance level by chance alone. In addition, the small sample sizes in the subgroups result in a reduced statistical power for detecting true relative differences. Therefore, a test of significance was performed only for the specified end point of sudden coronary heart disease death in the Beta-Blocker Heart At• tack Trial subgroup with complex ventricular premature beats, as defined in the protocol. Sudden death was defined as death from coronary heart disease, occurring less than 1 pour after the onset of symptoms. Instantaneous death, a subset of sudden death, was defined as death occurring abruptly, without symptoms.
Results
Baseline findings. Ambulatory electrocardiograms were performed at the baseline examination in 86.1 % (1,650 of 1916) of those randomized to propranolol and 85.4% (1,640 of 1,921) of those randomized to placebo. Examination of the baseline characteristics of those with and without am• bulatory electrocardiogram showed excellent agreement in most respects. Slightly more patients with ambulatory elec• trocardiograms had a history of angina (36.8 to 32.4%) and ST elevation on the electrocardiogram at rest (13.8 to 10.6%), whereas fewer patients with ambulatory electrocardiograms had T wave abnormalities on the electrocardiogram at rest (64.5 to 71.8%) and were using an antiarrhythmic drug in the hospital before randomization (45.2 to 50.5%). Table 1 shows baseline variables for the patients with the four classifications of ventricular arrhythmia, both treat• ment groups combined. In general, variables associated with increasing risk of mortality, such as age, history of prior myocardial infarction, presence of congestive heart failure, cardiomegaly and use of antiarrhythmic agents, diuretic agents and digitalis, were more common in patients meeting more stringent classifications of arrhythmia. For all four arrhyth• mia classifications, there was excellent baseline compara• bility between the propranolol and placebo-treated groups.
Mortality. Total mortality and cause-specific mortality, by treatment assignment, are shown in Table 2 for the four classifications of ventricular arrhythmia and for the patients *Protocol definition. BHAT = Beta-Blocker Heart Attack Trial; CHF = congestive heart failure; DBP = diastolic blood pressure; ECG = electrocardiogram; HR = heart rate; MI = myocardial infarctIOn; Non-BHAT MI = c1imcal myocardial mfarction not meeting Beta-Blocker Heart Attack Trial definitIOn; SBP = systolic blood pressure; VPB = ventricular premature beat without arrhythmia. In general, the placebo-treated patients having more stringent classifications of arrhythmia had higher event rates. Total mortality for patients with increasing grades of arrhythmias went from 10.9 to 15.2 to 19.9 to 19.6%, respectively. Sudden death, which accounts for about half of total mortality, increased from 5. 1 to 7.7 to 9.0 to 10.7 % , respectively. The other outcomes showed similar trends.
Regardless of the classification of arrhythmia, total and cause-specific mortality were higher among those patients with arrhythmia than among those without. Thus, for the patients with at least one ventricular premature beat, total mortality was 7.9 and 10.9% in the propranolol-and pla• cebo-treated groups, respectively. Among patients with no recorded ventricular premature beats, the mortality rate of the propranolol-treated group was 3.2% versus 5.0% for the placebo-treated group. Comparisons for other end point!> and classifications of arrhythmia show the same relations. In all except one case, the frequencies of events in the propranolol-treated group were less than those in the com• parable placebo-treated group (relative risk < 1). Table 2 also compares the relative risks (propranolol versus placebo) of the various outcomes in the four defined subgroups with the relative risks in the complementary groups. In many of the cases, the relative risks in the patients with arrhythmias were similar to those in the patients without arrhythmias. The major exception is the group meeting the most stringent classification of arrhythmia. Although there were only a few patients with this classification, the relative risks were uniformly greater than those in the patients with• out this arrhythmia.
The a priori subgroup hypothesis that sudden death would be preferentially reduced in patients with complex ventric• ular arrhythmias was not supported. The relative risk of sudden death for this subgroup was 0.72 versus 0.84 for the subgroup without ventricular arrhythmia, a 14% relative difference. The value of the Mantel-Haenszel chi-square analysis of homogeneity was 0.20 (l df), indicating that there is no statistical evidence of a difference between these results (p > 0.05). Using the other classifications of arrhythmia, no preferential effect of propranolol on sudden death was observed.
Concomitant therapy and compliance. The percent• ages of patients withdrawn from the study medication be• cause of adverse effects or with complaints at any time during the study are similar among the different classifi• cations of arrhythmia. There is no evidence that those pa• tients with arrhythmia who were receiving propranolol had a greater frequency of complaints or adverse effects than patients without arrhythmia. The propranolol-placebo com• parisons are similar to those for the study group as a whole (1). Table 3 shows the frequency of use of nonstudy drugs during the trial. Antiarrhythmic drugs were prescribed more often for the placebo-treated than for the propranolol-treated 5 BETA-BLOCKER HEART ATTACK TRIAL RESEARCH GROUP patients for all four classifications. Except for the patients meeting the most stringent classification of arrhythmia, non• study beta-receptor blockers were also used more frequently in the placebo-treated group. There was also a trend toward increasing use of diuretic drugs, digitalis and antiarrhythmic agents with the more stringent classifications. Table 4 . Compliance in the patients receiving propranolol decreased as the severity of arrhyth• mia increased. This is primarily because of an increase in the number of patients not taking any study medication and a decrease in the number receiving the full protocol dose.
Patient compliance to medication at the last completed study visit is shown in

Discussion
Propranolol and ventricular arrhythmia. Previous re• ports (15-17) of trials of beta-blockers claimed a reduction in sudden cardiac death, though the definitions of sudden death in those studies included mortality within 24 hours of the onset of symptoms. In addition, a decrease in ambient ectopic rhythm after administration of beta-blockers had been reported (18, 19) . Ventricular arrhythmia had been shown (8, 10, 20) to be an independent risk factor for sudden death and total mortality. Therefore, at the initiation of the Beta• Blocker Heart Attack Trial, it was postulated that much of any observed benefit would occur in those patients who had complex ventricular arrhythmias.
Analyses of data from the patients participating in the Beta-Blocker Heart Attack Trial who had both baseline and 6 week ambulatory electrocardiograms have confirmed the antiarrhythmic properties of propranolol (4). Among pa• tients with ventricular arrhythmia (defined as ventricular premature beats 2: 10th and pairs or runs) at baseline, the prevalence of arrhythmia at 6 weeks was 53% in the pro• pranolol-treated group as compared with 73% in the pla• cebo-treated group. Among patients with no baseline ar• rhythmia, the prevalence of arrhythmia at 6 weeks was 12% in the propranolol-treated group and 21 % in the placebo• treated group. In the latter group, the overall prevalence of ventricular premature beats was higher at 6 weeks than at baseline. This increase was blunted in the propranolol-treated group (4). Mortality and effect of propranolol. The data pre• sented here do not support the hypothesis that reduction in mortality due to propranolol is primarily restricted to those patients with ventricular arrhythmia at baseline. When the protocol-specified classification of arrhythmia is examined, the relative benefit of propranolol is similar, regardless of whether the patient had the arrhythmia. This holds for all• cause mortality, as well as coronary heart disease mortality and sudden cardiac death. These results are similar for two of the other three arrhythmia classifications (ventricular pre• mature beats> ° and 2: lO/h).
The presence of complex ventricular premature beats did identify a group of patients at approximately twice the risk of death as those without complex ventricular premature beats, though similar relative benefit from propranolol was Table 2 rRIEDMAN ET AL BETA-BLOCKER HEAR [ AfT ACK [RIAL RE~EARCH GRUUP observed. Therefore, for the ~ame number of patients treated, the high-risk group will have a greater absolute benelit from the drug (that is, more lives saved per number treated). Interestingly, little or no benefit from propranolol is found in those patients with the classification of arrhythmia re• quiring the most stringent criteria (ventricular premature beats ~ I ° plus pairs or runs plus multiform ventricular premature beats). This contrasts with the benefit noted in those without this arrhythmia. This might be a chance ob• servation, enhanced by the relatively small number of pa• tients and events in the arrhythmia subgroup. Another ex• planation is that the requirement for having frequent ventricular premature beats and pairs or run~ and multiform ventricular premature beats identifies patients not only at high risk of mortality, but also at high risk of being harmed by taking beta-blockers. Beta-blockers, as well as other antiar• rhythmic receptors, have at times been shown to be proar• rhythmic (21) . Thus, any benefit from the drug might be offset by toxicity. The use of diuretic drugs, digitali~ and antiarrhythmic agent~ was highest in this patient subgroup. These drugs may have played a role in minimizing the potential benefit from propranolol. It is also true that com• pliance to study medication was not as good in this subgroup of patients, possibly impairing the ability to detect benefit. if any, from propranolol.
Postulated mechanisms of propranolol's beneficial ef• fect. The observation that patients without arrhythmia ben• efited relatively as much from propranolol as those with arrhythmia, regardless of the c1a~sification. implies that there are mechanisms of action other than the reduction in ven• tricular ectopic rhythm. Propranolol has been shown (22.23) to increase the threshold for ventricular fibrillation. Thl~ effect may be distinct from its observed effect on ventricular premature beats. There appears to be an association, how• ever. between the presence of ventricular premature beat~ and the risk of fibrillation and sudden death (10.20,24,25) . although it is uncertain whether the association i~ greater than with nonsudden cardiac death (9, II , 26) . If the antl• fibriIlatory action were primary. one might have expected more benefit in patients with arrhythmia. The benefit from propranolol might relate to an anti-ischemic effect, either directly (27) or through suppression of ventricular arrhyth• mia (28) . Propranolol may also operate by blocking beta2-receptors, and thus, arrhythmia mediated through cate• cholamine-induced hypokalemia (29) . Whether the negative inotropic effect of propranolol or its bradycardic and hy• potensive actions affected mortality is unknown.
As previously reported (30) . using baseline clinical cri• teria (exclusive of ambulatory electrocardiogram) ascer• tained in the acute phase of the myocardial infarction, the patients participating in the Beta-Blocker Heart Attack Trial were retrospectively divided into four subgroups: those with electrical problems, those with mechanical or pump prob-JACC Vol 7. No I Janual) 1986 J -8 lem~, tho~e with both and those with neither. The three ~ubgroupi> with electncal or mechanical disturbance~, or both. appeared to benefit from propranolol therapy, showing reduced mortality. Limited benefit from thc drug was found in the subgroup without such problems. Thus, patients who experienced electrical disturbances (ventricular fibrillation, ventricular tachycardia. atrioventricular [A Vj block or atrial fibnllation) before enrollment in the Beta-Blocker Heart Attack Trial ~eemed to benefit more from propranolol than tho~e without electrical disturbances. This differs from the finding that patient~ with ventricular arrhythmias on an am• bulatory electrocardiogram recorded an average of 2 weeks after hospital admission did no better while taking propran• olol. relative to placebo. than patients without such arrhyth• mia~. The reason for this di~crepancy may be that the clinical as~eSf>ment relied on finding~ early in the course of the infarction. while the ambulatory electrocardiogram was per• tormed in the convalescent phase. It has been reported that arrhythmia~. particularly ventricular fibrillation, occurring in the first few days of a myocardial infarction have little or no independent association with subsequent arrhythmias or mortality 01-35). although thi~ finding has been ques• tioned (25.36) . In addition. the difference in the Beta-Blocker Heart Attack Trial rei>ults may reHect the fact that the am• bulatory electrocardiogram record!> episodes in one 24 hour period, wherea~ clinical findings occur over several days.
Summary. The hypothe5is that propranolol would be of speCial benefit in patients with prior myocardial infarction who have ventncular anhythmia was not supported. The presence of arrhythmia on an ambulatory electrocardiogram, however, can Identify high-risk patienb. Because the per• cent mortality i~ higher in ;,uch patlcnts. the !>imilar relative benefit lead~ to a greater absolute benefit in those receiving propranolol. With more lives ~aved per number treated. The mechanism of action by which propranolol reduces mortality i~ probably not solely an antiarrhythmic one.
